GSK To Put Up To $7.2B Into Biotech VC's Pipeline
GlaxoSmithKline said Monday it is investing up to $7.2 billion in a biotech venture capital firm's research and development pipeline, focusing on treatments for respiratory and immune problems....To view the full article, register now.
Already a subscriber? Click here to view full article